Taken together, our data point to a mechanism whereby the antiproliferative properties of propionate and butyrate in CRC can be attributed to their dysregulation of key CRC oncogenes such as MYC, FOS and JUN, as well their simultaneous triggering of downregulation of genes controlling cell cycle and cell division. The gene discussed is FOS; the disease is colorectal carcinoma.